INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...
Nasdaq

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries Dr. Matthew ...
Yahoo Finance

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients ...
Monthly Prescribing Reference

DNA Therapy Gets Breakthrough Status for Recurrent Respiratory Papillomatosis

Credit: Shutterstock. Recurrent respiratory papillomatosis is caused primarily by HPV types 6 and 11. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INO-3107 ...